Work

The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.11085

Authors: Marc Ladanyi, Phil T. Cagle, Mary Beth Beasley, Dhananjay Chitale, Sanja Dacic, Giuseppe Giaccone, Robert B. Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Neal Ian Lindeman

Institutions: Memorial Sloan Kettering Cancer Center, Houston Methodist, Henry Ford Health, University of Pittsburgh, National Institutes of Health, National Cancer Institute, Mayo Clinic, Dana-Farber Cancer Institute, City Of Hope National Medical Center, Queen's University, Amsterdam UMC Location Vrije Universiteit Amsterdam, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2625444591

Cites:

Cited by: 5

Related to: 10